CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,748,386 | -11.5% | 462,286 | -46.4% | 3.96% | +2.2% |
| Q2 2023 | $15,538,394 | +12.2% | 862,286 | 0.0% | 3.87% | +9.3% |
| Q1 2023 | $13,848,313 | -12.2% | 862,286 | 0.0% | 3.54% | -16.5% |
| Q4 2022 | $15,779,834 | -6.8% | 862,286 | 0.0% | 4.24% | +30.7% |
| Q3 2022 | $16,935,000 | +5.3% | 862,286 | 0.0% | 3.24% | -18.5% |
| Q2 2022 | $16,082,000 | -15.0% | 862,286 | 0.0% | 3.98% | -3.7% |
| Q1 2022 | $18,927,000 | -22.7% | 862,286 | 0.0% | 4.13% | -10.1% |
| Q4 2021 | $24,498,000 | -14.6% | 862,286 | -36.7% | 4.60% | -21.0% |
| Q3 2021 | $28,676,000 | +11.7% | 1,362,286 | 0.0% | 5.82% | -9.9% |
| Q2 2021 | $25,679,000 | +23.4% | 1,362,286 | 0.0% | 6.46% | +72.4% |
| Q1 2021 | $20,816,000 | +8.3% | 1,362,286 | 0.0% | 3.75% | -42.1% |
| Q4 2020 | $19,222,000 | -10.0% | 1,362,286 | 0.0% | 6.47% | +15.3% |
| Q3 2020 | $21,347,000 | -10.6% | 1,362,286 | 0.0% | 5.61% | +7.4% |
| Q2 2020 | $23,867,000 | -12.8% | 1,362,286 | -26.8% | 5.23% | -38.3% |
| Q1 2020 | $27,376,000 | -53.8% | 1,862,286 | -21.2% | 8.48% | -33.5% |
| Q4 2019 | $59,270,000 | – | 2,362,286 | – | 12.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |